Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia.

ABSTRACT:

Introduction

Plasma biomarkers sensitive to Alzheimer's disease (AD) proteinopathy prior to the onset of dementia have significant implications for early detection.

Methods

In 304 individuals without dementia, we investigated whether C₂N Diagnostics' mass spectrometry (MS)-based plasma biomarkers (amyloid beta 42/40, %phosphorylated tau [p-tau]181, and %p-tau217) and amyloid probability scores (APS, PrecivityAD and APS2, PrecivityAD2) are associated with brain amyloid, brain tau, or preclinical cognitive decline.

Results

In this cohort study, %p-tau217 and the APS2 had high discriminative accuracy (area under the curve > 0.93) for identifying elevated brain amyloid and tau and were associated with faster preclinical cognitive decline. Using %p-tau217 or the

SUBMITTER: Cody KA 

PROVIDER: S-EPMC11922805 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature